Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Discrimination of the Activity of Low-Affinity Wild-Type and High-Affinity Mutant Recombinant BoNT/B by a SIMA Cell-Based Reporter Release Assay.

Toxins - 17 Jan 2022

Neuschäfer-Rube Frank, Pathe-Neuschäfer-Rube Andrea, Püschel Gerhard P

Abstract excerpt

Botulinum neurotoxin (BoNT) is used for the treatment of a number of ailments. The activity of the toxin that is isolated from bacterial cultures is frequently tested in the mouse lethality assay. Apart from the ethical concerns inherent to this assay, species-specific differences in the affinity for different BoNT serotypes give rise to activity results that differ from the activity in humans. Thus, BoNT/B is...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Bacterial Toxins
Share to Biological Assay

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Cell Line

Share to Mutation

Share to Recombinant Proteins

Source

Open in PubMed Open full text

Identifiers

PMID: 35051041
DOI: 10.3390/toxins14010065
PMCID: PMC8780439

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Discrimination of the Activity of Low-Affinity Wild-Type and High-Affinity Mutant Recombinant BoNT/B by a SIMA Cell-Based Reporter Release Assay.PMID 35051041Read ↗

Embracing the Versatility of Botulinum Neurotoxins in Conventional and New Therapeutic ApplicationsSemantic proximity Read ↗

The Light Chain Defines the Duration of Action of Botulinum Toxin Serotype A SubtypesSemantic proximity Read ↗

Potency Evaluations of Recombinant Botulinum Neurotoxin A1 Mutants Designed to Reduce Toxicity.Semantic proximity Read ↗

Therapeutic Applications of Botulinum Neurotoxins in Veterinary MedicineSemantic proximity Read ↗

Clostridium botulinum Neurotoxins Act with a Wide Range of Potencies on SH-SY5Y Human Neuroblastoma CellsSemantic proximity Read ↗

Botulinum Toxin: A Comprehensive Review of Its Molecular Architecture and Mechanistic ActionSemantic proximity Read ↗

Novel therapeutics based on recombinant botulinum neurotoxins to normalize the release of transmitters and pain mediators.Semantic proximity Read ↗

Characterization of a membrane binding loop leads to engineering botulinum neurotoxin B with improved therapeutic efficacy.Semantic proximity Read ↗

Challenges in searching for therapeutics against Botulinum NeurotoxinsSemantic proximity Read ↗

A dileucine in the protease of botulinum toxin A underlies its long-lived neuroparalysis: transfer of longevity to a novel potential therapeutic.Semantic proximity Read ↗

A novel bioassay for quantification of surface Cannabinoid receptor 1 expression.Semantic proximity Read ↗

New Engineered-Chimeric Botulinum Neurotoxin Mutant Acts as an Effective Bivalent Vaccine Against Botulinum Neurotoxin Serotype A and E.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.